Literature DB >> 30198757

Development and effects of a self-management efficacy promotion program for adult patients with congenital heart disease.

Mi-Ja Lee1,2, Dukyoo Jung2.   

Abstract

BACKGROUND: With the recent advances in medicine, patients with congenital heart disease are surviving to adulthood. Adults with congenital heart disease must practice self-management to recognize the symptoms of complications and the appropriate response. AIMS: The purpose of this study was to develop a self-management efficacy promotion program for adults with congenital heart disease and to test the effects of the developed program on disease-related knowledge, self-management implementation and health-related quality of life.
METHODS: A non-equivalent, control group, pre-post test design was used. The intervention group received the self-management efficacy promotion program for six weeks. The control group received only the usual care.
RESULTS: The study results showed that disease-related knowledge ( F=91.095, p<0.001) was significantly different between the two groups, as was the self-management performance ( F=11.846, p<0.001). However, health-related quality of life (generic core scale: F=0.023, p=0.881, cardiac module scale: F=0.174, p=0.678) was not significantly different between groups.
CONCLUSION: The self-management efficacy promotion program for adults with congenital heart disease had a significant effect on disease-related knowledge and self-management implementation, but did not affect health-related quality of life.

Entities:  

Keywords:  Adults with congenital heart disease; quality of life; self-efficacy; self-management

Mesh:

Year:  2018        PMID: 30198757     DOI: 10.1177/1474515118800099

Source DB:  PubMed          Journal:  Eur J Cardiovasc Nurs        ISSN: 1474-5151            Impact factor:   3.908


  1 in total

1.  Process evaluation of complex cardiovascular interventions: How to interpret the results of my trial?

Authors:  Markus Saarijärvi; Lars Wallin; Ewa-Lena Bratt
Journal:  Eur J Cardiovasc Nurs       Date:  2020-02-14       Impact factor: 3.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.